---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-234504"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2023-09-13T23:59:59+00:00"
generated_at: "2026-06-10T19:08:56.731672+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics upsizes public offering to $350M gross; prices 11.44M shares at $30.59

## Summary
- Priced upsized offering of 11,441,648 shares at $30.59 per share, expected gross proceeds ~$350M.
- Net proceeds expected ~$328.6M; ~$378M if underwriters' 30-day option for 1.72M additional shares is exercised.
- Proceeds to fund development of paltusotine, CRN04894, and other R&D programs; closing expected Sept 15, 2023.
- Initial announcement on Sept 11 targeted $250M; offering upsized to $350M at pricing on Sept 12.
- J.P. Morgan, Morgan Stanley, Leerink, and Piper Sandler act as joint book-running managers.

## SEC filing metadata
- accession: 0001193125-23-234504
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2023-09-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312523234504/0001193125-23-234504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312523234504/d465389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-234504
- JSON: https://secwatch.observer/filing/0001193125-23-234504.json
- Plain text: https://secwatch.observer/filing/0001193125-23-234504.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.